Trial Profile
An open-label safety and pharmacokinetic study of gevokizumab in subjects with Behçet's disease uveitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Apr 2018
Price :
$35
*
At a glance
- Drugs Gevokizumab (Primary) ; Gevokizumab (Primary)
- Indications Behcet's syndrome; Uveitis
- Focus Adverse reactions
- 26 Apr 2017 New trial record